Complete financial analysis of NOXXON Pharma N.V. (ALNOX.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NOXXON Pharma N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- Century Lithium Corp. (LCE.V) Income Statement Analysis – Financial Results
- TORICO Co., Ltd. (7138.T) Income Statement Analysis – Financial Results
- 3SBio Inc. (1530.HK) Income Statement Analysis – Financial Results
- Basler Kantonalbank (0QLU.L) Income Statement Analysis – Financial Results
- KMC (Kuei Meng) International Inc. (5306.TW) Income Statement Analysis – Financial Results
NOXXON Pharma N.V. (ALNOX.PA)
About NOXXON Pharma N.V.
NOXXON Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck & Co. Inc. to study NOX-A12 combined with Keytruda/pembrolizumab inhibitor antibody in patients with metastatic solid tumors. NOXXON Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.00K | 43.00K | 25.00K |
| Cost of Revenue | 0.00 | 0.00 | 1.03M | 982.00K | 959.00K | 1.46M | 2.64M | 3.68M |
| Gross Profit | 0.00 | 0.00 | -1.03M | -982.00K | -959.00K | -1.38M | -2.60M | -3.65M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,657.83% | -6,044.19% | -14,612.00% |
| Research & Development | 10.66M | 4.02M | 496.00K | 479.00K | 402.00K | 1.03M | 906.00K | 1.50M |
| General & Administrative | 1.27M | 912.00K | 1.32M | 1.29M | 1.13M | 2.30M | 4.97M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 263.00K | 307.00K | 409.00K | 149.00K |
| SG&A | 1.27M | 912.00K | 1.32M | 1.29M | 1.40M | 2.60M | 5.38M | 1.56M |
| Other Expenses | 1.53M | 822.00K | 1.10M | 1.57M | 1.97M | 3.40M | 5.40M | 6.45M |
| Operating Expenses | 13.45M | 5.75M | 2.92M | 3.34M | 3.77M | 7.03M | 11.68M | 9.50M |
| Cost & Expenses | 13.45M | 5.75M | 3.94M | 4.32M | 4.73M | 8.49M | 14.32M | 13.18M |
| Interest Income | 319.00K | 418.00K | 3.09M | 388.00K | 1.02M | 1.00K | 0.00 | 3.00K |
| Interest Expense | 1.50M | 5.06M | 3.00K | 6.76M | 1.68M | 2.13M | 1.29M | 632.00K |
| Depreciation & Amortization | 66.00K | 63.00K | 47.00K | 23.00K | 29.00K | 340.00K | 218.00K | 279.00K |
| EBITDA | -12.88M | -5.29M | -810.00K | -3.95M | -3.68M | -8.25M | -14.61M | -12.88M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,943.37% | -33,981.40% | -51,536.00% |
| Operating Income | -12.95M | -5.35M | -857.00K | -3.98M | -3.71M | -8.59M | -14.83M | -13.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -10,353.01% | -34,488.37% | -52,652.00% |
| Total Other Income/Expenses | -1.51M | -5.06M | -3.00K | -6.76M | -1.68M | -2.13M | -1.29M | -632.00K |
| Income Before Tax | -14.45M | -10.41M | -860.00K | -10.74M | -5.39M | -10.73M | -16.12M | -13.80M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,921.69% | -37,497.67% | -55,180.00% |
| Income Tax Expense | 1.00K | 5.06M | 1.00K | 1.00K | 1.00K | 27.00K | -22.00K | 3.00K |
| Net Income | -14.45M | -15.46M | -861.00K | -10.74M | -5.39M | -10.75M | -16.10M | -13.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -12,954.22% | -37,446.51% | -55,192.00% |
| EPS | -45.99 | -47.78 | -7.72 | -269.86 | -253.81 | -536.18 | -802.97 | -688.08 |
| EPS Diluted | -45.99 | -47.78 | -7.72 | -269.86 | -253.81 | -536.18 | -802.97 | -688.08 |
| Weighted Avg Shares Out | 314.27K | 323.59K | 111.58K | 39.79K | 21.24K | 20.05K | 20.05K | 20.05K |
| Weighted Avg Shares Out (Dil) | 314.27K | 323.59K | 111.58K | 39.79K | 21.24K | 20.05K | 20.05K | 20.05K |
Source: https://incomestatements.info
Category: Stock Reports